ArticleFish physiology and biochemistry2026
Nutritional intervention with glycyrrhetinic acid (GA) enhances growth and metabolic balance in channel catfish (Ictalurus punctatus) fed a high-fat diet.
Article in Fish physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the protective effects of glycyrrhetinic acid (GA) supplementation on metabolic disturbances induced by a high-fat diet (HFD) in juvenile channel catfish (Ictalurus punctatus). Fish were fed a control diet, an HFD, or an HFD supplemented with 0.4, 0.8, and 1.2 mg/kg GA, respectively, for 8 weeks. Hepatic function, mitochondrial integrity, and metabolic gene expression were assessed. HFD significantly impaired protein efficiency ratio (PER) and relative feed intake (RFI) while promoting excessive lipid deposition and energy storage. These changes were accompanied by elevated plasma levels of liver enzymes (GOT, GPT), non-esterified fatty acids (NEFA), and pro-inflammatory cytokines (TNF-α, IL-6, MCP-1). Mitochondrial dysfunction was evident from reduced activities of succinate dehydrogenase, Na⁺, K⁺-ATPase, and complexes I and II, alongside increased cytosolic cytochrome c, indicating mitochondrial injury and apoptosis. HFD also suppressed expressions of mitochondrial genes (nd1, cytb) and disrupted glucose and lipid metabolism by altering key gene expression patterns. GA supplementation significantly reversed these pathological changes. It improved mitochondrial function, restored respiratory complex activities (particularly complex III), normalized gene expression related to mitochondrial biogenesis, glucose utilization (e.g., ampkα2, glut2), and lipid oxidation (e.g., cpt1, pparα), and reduced inflammation and hepatic damage. Overall, GA redirected energy utilization from lipid storage toward growth, suggesting its potential as a functional feed additive to mitigate high-fat diet-induced metabolic dysfunction in aquaculture species.
Indexed as
Identifiers
41945159What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.